



This is a repository copy of *Recommendations from the AML molecular MRD expert advisory board*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/214554/>

Version: Published Version

---

**Article:**

Scott, S. [orcid.org/0000-0001-8182-3057](https://orcid.org/0000-0001-8182-3057), Devonshire, A. [orcid.org/0000-0003-4960-5468](https://orcid.org/0000-0003-4960-5468), Dillon, R. [orcid.org/0000-0001-9333-5296](https://orcid.org/0000-0001-9333-5296) et al. (16 more authors) (2024)  
Recommendations from the AML molecular MRD expert advisory board. *Leukemia*, 38. pp. 1638-1641. ISSN 0887-6924

<https://doi.org/10.1038/s41375-024-02275-x>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## CORRESPONDENCE

## OPEN



## ACUTE MYELOID LEUKEMIA

# Recommendations from the AML molecular MRD expert advisory board

© The Author(s) 2024

*Leukemia* (2024) 38:1638–1641; <https://doi.org/10.1038/s41375-024-02275-x>

**TO THE EDITOR:**

The standard-of-care treatment for patients with acute myeloid leukemia (AML) is being challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors [1]. Contemporaneously, measurable residual disease (MRD) testing is being considered as a surrogate for traditional clinical outcomes in the clinical trials of these new therapies [2]. To successfully integrate MRD assays into clinical trials, testing must be standardized between laboratories to ensure results are comparable in multicentre MRD assessment studies. Thus, results from different clinical trials can be meaningfully compared and, ultimately, clinical thresholds around common MRD levels applicable to all AML patients globally can be developed for these new treatments.

To this end, the European LeukemiaNet (ELN) group published recommendations in 2018 [3], updated in 2021, that standardized the technical and reporting aspects of AML MRD testing for reverse transcription PCR (RT-PCR) and flow cytometry based approaches, with the 2021 update extending this to next generation sequencing (NGS) analysis and the use of MRD as a surrogate marker in clinical trials. Further to this, external quality assessment (EQA) programs have been established to assess the quality of testing [4]. For molecular MRD testing, EQA data has shown that interlaboratory variation for molecular AML MRD testing was substantially greater than that seen for *BCR::ABL1* testing in chronic myeloid leukemia (CML), despite both tests being reverse transcription quantitative PCR-based (Fig. 1) [5, 6]. However, *BCR::ABL1* MRD testing has been subject to many years of standardization, including the development of the *BCR::ABL1* international scale (IS) [7].

An expert advisory board was established through the NHS Chief Scientific Officer's Knowledge Transfer Partnership program to assess how molecular AML MRD testing could be further standardized [8]. This letter represents the findings of the board. The advisory board was composed of experts, including clinical scientists working in the establishment of UK AML MRD testing and those leading the standardization of *BCR::ABL1* testing in CML, clinicians experienced in managing patients with AML-based on MRD testing results, measurement science (metrology) experts and reference material producers. Representatives from commercial providers involved in manufacturing in vitro diagnostic (IVD) kits, reference standards and instrumentations were also present. Finally, representatives were present from the ELN David group. The Foundation for the National Institute of Health (FNIH)

Biomarkers Consortium were consulted outside of the meeting. ELN David and the FNIH Biomarkers Consortium are both active in AML MRD standardization and were approached to ensure that any standardization recommendations were complementary to the activities of these groups.

The stated aims of the expert advisory board were to answer the following questions:

1. Would further standardization of molecular AML MRD be beneficial?
2. What markers should be standardized?
3. How should the standardization of these markers be prioritized?
4. What would be the best approaches to standardizing these markers?

To expedite the workings of the board, several surveys were performed in advance of the meeting: one for the experts involved in the meeting, one for the laboratories currently performing molecular AML MRD testing and another for commercial providers of IVDs, standards and platforms (Supplementary Tables 1–6).


The recommendations of the board and pre-board survey have been outlined below:

- All board members felt further standardization of molecular AML MRD testing would be beneficial to the field.
- The main blocks to standardization cited by EQA participants were lack of time and money (Supplementary Table 1), therefore, any standardization efforts should be easy to implement and inexpensive (Supplementary Table 2).
- Standardization of *RUNX1::RUNX1T1*, *CBFB::MYH11* type A and *NPM1* type A testing by RT-PCR-based approaches was deemed to be the priority (Supplementary Table 3). These markers are some of the most prevalent somatic changes found in patients with AML. Furthermore, there are commercially available cell lines facilitating standardization projects. Despite the high prevalence of the *PML::RARA* rearrangement in AML patients, *PML::RARA* MRD testing is primarily interpreted qualitatively thus limiting the impact of any standardization projects [3].
- RT-PCR-based testing of *NPM1* type B and D and *FLT3* internal tandem duplications (ITD) should be considered for future standardization projects. *NPM1* type B and D are only found in around 10% and 8% of *NPM1* positive patients with AML, respectively, compared to 70% who have the *NPM1* type A variant [9]; however, this is still a substantial number of patients and standardization should be considered if stable cell lines can be produced. Cell lines for *NPM1* type B and D

Received: 21 February 2024 Revised: 5 April 2024 Accepted: 30 April 2024  
Published online: 23 May 2024

should be developed to facilitate future standardization projects. Despite recent publications showing the prognostic importance of *FLT3* ITD MRD testing [10], it is not yet clear how this testing will be employed and what the clinically important cut-offs will be, thus it would be premature to begin standardizing testing.


- The development of higher order, primary reference materials (RMs) was the priority of the board (Supplementary Table 4). Primary RMs are at the top of the calibration hierarchy from which other quality control (QC) materials can be calibrated (Fig. 2).
- Internationally recognized certification would be important to



**Fig. 1** Comparison of interlaboratory variation for standardized *BCR::ABL1<sup>IS</sup>* RT-dPCR (gray triangle markers) and RT-qPCR (black triangle markers) [5] testing with unstandardized *RUNX1::RUNX1T1* (blue circle markers), *CBFB::MYH11* (red circle markers), *PML::RARA* (green circle markers) and *NPM1* (orange circle markers) RT-qPCR testing [6].

any reference materials produced, as is compliance with the European Union In Vitro Diagnostics Regulation (EU-IVDR). Certification of reference materials demonstrates that the material has been produced to a high standard, assuring laboratories of its quality, driving uptake. The EU-IVDR regulation, Chapter 1, Section 1, Article 1, point 3 specifically exempts certified reference materials (CRMs); however, they do require any IVD in-kit controls or calibrators to demonstrate traceability to reference materials of a higher metrological order; therefore, any reference materials produced should be of a sufficient order to satisfy this requirement and be available to IVD manufacturers for this purpose.

- The pre-board surveys suggested ISO 17034:2016 [11] or ISO 13485:2016 [12] would be the most appropriate form of certification for any reference materials produced (Supplementary Table 5); however, further discussion in the meeting suggested that *manufacturing reference materials according to World Health Organization (WHO) guidelines [13] and approval by the WHO Expert Committee on Biological Standardization (ECBS) would be the most appropriate approach given the current context of AML MRD testing where a reference method is not currently available.*
- Higher order CRMs for RT-PCR based assays should be cell based as this allows for full process control, capturing the uncertainty generated in the RNA extraction and cDNA synthesis processes known to impact on the final normalized ratio result (Supplementary Table 6).
- Values for RT-PCR based MRD assays should only be assigned to any reference materials produced using *ABL1* as a reference gene to encourage standardization. Most laboratories performing molecular AML MRD testing use the *ABL1* reference gene to normalize testing results; however, a small subset uses alternative reference genes, such as *GUSB*, *B2M* and *HMBS*. The use of non-*ABL1* reference genes by



**Fig. 2** Structure of a calibration hierarchy whereby patient results are traceable to higher order reference materials such as World Health Organisation (WHO) International Standard materials, through a series of linked calibrations. An example of this is in the standardization of *BCR::ABL1*/reference gene ratio to the International Scale. Modified from ISO 17511:2020 Figure 4 model calibration hierarchy for "international conventional calibrator" that defines the quantity intended to be measured ("measurand") [15]. IVD, in vitro diagnostic medical device. Created with BioRender.com.

around 15% of laboratories has proven problematic to the standardization of *BCR::ABL1* in CML, with conversion factors relating to *GUSB* being shown to be potentially more unstable when compared with their *ABL1* counterparts despite extensive standardization [14].

- *The development of research use only (RUO) or QC materials calibrated to the primary CRM would also be beneficial to the field.*

These recommendations should act as a starting point for commercial and academic consortia to work together to develop the resources outlined above to ensure that clinical trials results, and ultimately the management of patients with AML, are both based on the highest quality data possible.

Stuart Scott<sup>1,2</sup>✉, Alison Devonshire<sup>3</sup>, Richard Dillon<sup>4,5</sup>, Christian Thiede<sup>6,7</sup>, Nicholas C. P. Cross<sup>8,9</sup>, Helen E. White<sup>8,9</sup>, Leandro Lo Cascio<sup>10</sup>, Katya Mokretar<sup>11</sup>, Nicola Potter<sup>12</sup>, Christopher S. Hourigan<sup>12</sup>, Jerald Radich<sup>13</sup>, Adam Corner<sup>14</sup>, Véronique Laloux<sup>15</sup>, Gemma Halliday<sup>16</sup>, Daniel Dilks<sup>17</sup>, Tom Morrison<sup>17</sup>, Katelyn Gilmour<sup>18</sup>, Ashley Cartwright<sup>1</sup> and Liam Whitby<sup>1</sup>

<sup>1</sup>UK NEQAS for Leucocyte Immunophenotyping, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. <sup>2</sup>Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.

<sup>3</sup>Molecular and Cell Biology, National Measurement Laboratory, LGC, Teddington, UK. <sup>4</sup>Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK. <sup>5</sup>Department of Medical and Molecular Genetics, King's College, London, UK. <sup>6</sup>University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany. <sup>7</sup>Agendix, Applied Molecular Diagnostics, GmbH, Dresden, Germany. <sup>8</sup>Faculty of Medicine, University of Southampton, Southampton, UK. <sup>9</sup>Wessex Genomics Laboratory Service, Salisbury District Hospital, Salisbury, UK. <sup>10</sup>Diagnostics R&D, Medicines and Healthcare Products Regulatory Agency (MHRA), Potters Bar, UK.

<sup>11</sup>Cancer Genetics, Guy's Hospital, Synnovis, London, UK. <sup>12</sup>Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, Bethesda, MD, USA. <sup>13</sup>Translational Science & Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. <sup>14</sup>Digital Biology Group, Bio-Rad Laboratories, Pleasanton, CA, USA. <sup>15</sup>Translational Science and Precision Diagnostics, QIAGEN, Courtaboeuf, France. <sup>16</sup>Horizon Discovery, Diagnostic Reference Standards, Cambridge, UK. <sup>17</sup>Accugenomics, Inc., Wilmington, NC, USA. <sup>18</sup>Clinical NGS and Oncology Division, Thermo Fisher, Paisley, UK. ✉email: [stuart.scott@ukneqasli.co.uk](mailto:stuart.scott@ukneqasli.co.uk)

## REFERENCES

- Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. *J Hematol Oncol.* 2023;16:1–27.
- United States Food and Drug Administration. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment Guidance for Industry. 2020 Jan. United States Food and Drug Administration. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and> (accessed 4 Aug 2023).
- Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. *Blood.* 2018;131:1275–91.
- UK NEQAS LI Home Page - Measurable Residual Disease for AML by Molecular Methods (Pilot - Not Accredited). <https://www.ukneqasli.co.uk/eqa-pt-programmes/molecular-haemato-oncology-programmes/measurable-residual-disease-for-aml-by-molecular-methods-pilot-not-accredited/> (accessed 4 Aug 2023).
- Scott S, Cartwright A, Francis S, Whitby L, Sanzone AP, Mulder A, et al. Assessment of droplet digital polymerase chain reaction for measuring *BCR-ABL1* in chronic myeloid leukaemia in an international interlaboratory study. *Br J Haematol.* 2021;194:53–60.
- Scott S, Dillon R, Thiede C, Sadiq S, Cartwright A, Clouston HJ, et al. Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. *Blood Adv.* 2023;7:3686–94.
- White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of *BCR-ABL* mRNA. *Blood.* 2010;116:111–17.
- Leaders and aspiring leaders in healthcare science - National Physical Laboratory. <https://www.npl.co.uk/leaders-in-healthcare-science> (accessed 10 Oct 2023).
- Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, et al. Molecular subtypes of *NPM1* mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. *Haematologica.* 2016;101:e55–8.
- Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. *JAMA.* 2023;329:745–55.
- International Organization for Standardization. ISO 17034:2016—General requirements for the competence of reference material producers. Available from: <https://www.iso.org/standard/29357.html> (accessed 9 Aug 2023).
- International Organization for Standardization. ISO 13485:2016—Medical devices—Quality management systems—Requirements for regulatory purposes. Available from: <https://www.iso.org/standard/59752.html> (accessed 9 Aug 2023).
- WHO. Expert Committee on Biological Standardization WHO Expert Committee on Biological Standardization: Fifty-ninth report. WHO Technical Report Series 2012;1-240. Available from: <https://www.who.int/groups/expert-committee-on-biological-standardization>.
- White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. *Leukemia.* 2022;36:1834–42.
- International Organization for Standardization. ISO 17511:2020 In vitro diagnostic medical devices — Requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples. 2020. Available from: <https://www.iso.org/standard/69984.html> (accessed 9 Aug 2023).

## AUTHOR CONTRIBUTIONS

SS produced the advisory board pre-read and pre-board surveys, chaired the advisory board, analyzed the survey data, and wrote the letter. AD reviewed the pre-read, survey, contributed to the advisory board, designed Fig. 2 and reviewed the letter. RD assisted with the pre-read, contributed to the advisory board, and reviewed the survey and letter. CT, NC, HW, LLC, KM, NP, and AD reviewed the pre read, surveys, contributed to the advisory board, and reviewed the letter. CH, JR, AC, VL, GH, DD, TM, KG, AC, and LW reviewed the pre-read, surveys, contributed to the advisory board, and reviewed the letter.

## COMPETING INTERESTS

Whilst the diverse composition of the panel brought a breadth of expertise and perspectives, it also introduced potential conflicts of interest, particularly regarding the commercial providers. These entities may have a vested interest in the outcomes of the advisory panel due to their affiliations and the nature of their businesses. Each member has disclosed their respective affiliations with commercial bodies. The discussion was led by individuals from non-commercial entities and all recommendations and findings have been derived through consensus and with the commitment to advancing clinical and laboratory practice. These disclosures have been made explicit to uphold transparency and integrity in the reporting of the panel's findings.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41375-024-02275-x>.

**Correspondence** and requests for materials should be addressed to Stuart Scott.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024